Carcinoma Cervix and Hiv: A Retrospective Study and Outcome

Background: Carcinoma cervix is a major global health problem, particularly in resource-limited settings. Co-existing human immunodeficiency virus (HIV) infection worsens disease progression, complicates treatment, and adversely affects prognosis.Aim: To assess the impact of HIV on clinical presentation, treatment response, and outcomes in patients with cervical cancer.Materials and Methods: A retrospective observational study was conducted at the Department of Radiation Oncology, PMT Loni, Maharashtra. Five HIV-positive patients with histopathologically confirmed carcinoma cervix treated with concurrent chemoradiotherapy (CTRT) were evaluated. Data on demographics, FIGO stage, CD4 counts, treatment details, toxicities (CTCAE v5), and response (RECIST 1.1) were analyzed.Results: Patients were aged 46–74 years; two had stage I disease, two stage II, and one stage III. Late treatment-related toxicities occurred in three patients (60%). Two patients (40%) developed recurrence within one year, while two (40%) achieved complete response.Conclusion: HIV infection negatively influences treatment tolerance and outcomes in carcinoma cervix. Early HIV detection, optimized antiretroviral therapy, and close immune monitoring are crucial for improving prognosis.